Panelists discuss best practices for patient education and engagement when introducing CDK4/6 inhibitors in metastatic breast cancer care.
Advancing Care in Metastatic Breast Cancer: Insights, Data, and Practical Strategies
Panelists discuss the long-term safety and durability of CDK4/6 inhibitors, highlighting data supporting sustained efficacy and manageable toxicity over years of treatment.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Lynkuet Access Program Aims to Help Women Save on Neurokinin-Targeted Therapy
2
Fall 2025 Quiz: Test Your Pharmacy Knowledge!
3
FDA Approves Elinzanetant as First Nonhormonal Therapy for Menopause Vasomotor Symptoms
4
New Data Show Elinzanetant Is a Safe, Well-Tolerated Non-Hormonal Therapy for Menopausal Vasomotor Symptoms
5
